Puma Biotechnology (PBYI)

$7.24 -0.24 (-3.21%)
Market Cap 380.67M
Revenue (ttm) 228.37M
Net Income (ttm) 31.11M
EPS (ttm) N/A
PE Ratio 12.41
Forward PE 54.07
Profit Margin 13.62%
Debt to Equity Ratio 0.17
Volume 335,700
Avg Vol 387,364
Day's Range N/A - N/A
Shares Out 50.89M
Stochastic %K 49%
Beta 1.19
Analysts Hold
Price Target $5.00

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 424 248 6500
Address:
10880 Wilshire Boulevard, Suite 1700, Los Angeles, United States
Jonnyking
Jonnyking Apr. 8 at 10:09 PM
$PBYI It is coming?
3 · Reply
focafoca99
focafoca99 Apr. 3 at 9:04 PM
$PBYI granted inducement RSUs covering 31,625 shares to five new non-executive employees.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 2 at 3:53 PM
$PBYI Share Price: $6.93 Contract Selected: Sep 18, 2026 $10 Calls Buy Zone: $0.21 – $0.26 Target Zone: $0.40 – $0.49 Potential Upside: 79% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MahiMe
MahiMe Mar. 30 at 7:08 PM
$PBYI Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 16 at 7:54 PM
$PBYI RSI: 33.64, MACD: -0.1848 Vol: 0.59, MA20: 6.50, MA50: 6.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 14 at 2:54 PM
Big opportunity in HER2 at $RADX (Radiopharm Theranostics) $CELC $SMMT $PBYI
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 4:41 PM
$IRWD vs. $PBYI — Which small-cap biotech actually has the edge right now? Both companies are building around a single commercial drug, and sales from those therapies are expected to support their 2026 revenues—GI treatments for Ironwood and cancer therapy from Puma Biotechnology. That puts a lot of weight on how those products perform. ⚖️ See which stock looks like the better buy 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-teaser-37187&ADID=SYND_STOCKTWITS_TWEET_2_2883283_TEASER_37187
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 3:41 PM
$IRWD vs. $PBYI: Which Biotech Stock is the Better Bet? 🤔 Ironwood's Linzess sales outlook shows a promising 54% revenue boost in 2026, while Puma's Nerlynx faces a cautious growth path despite rising demand. Plus, IRWD's EPS is expected to increase by 533% in 2026! 🚀 Discover why Ironwood might be the smarter pick here 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-body-37188&ADID=SYND_STOCKTWITS_TWEET_2_2883283_BODY_37188
0 · Reply
Jonnyking
Jonnyking Mar. 11 at 5:20 PM
$PBYI Alan, for once, please share the positive data with us, you promised on Q4 2025, then Q1 2026 and now Q2 2026.... Only the positive data can save you and us
2 · Reply
free2dream
free2dream Mar. 5 at 5:21 PM
$PBYI how is this valued at only 313M market cap ?Seems undervalued
0 · Reply
Latest News on PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 5:15 PM EDT - 14 days ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:05 PM EST - 7 weeks ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

Feb 23, 2026, 4:15 PM EST - 7 weeks ago

Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:07 PM EST - 2 months ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Dec 22, 2025, 4:10 PM EST - 4 months ago

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 5 months ago

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Oct 23, 2025, 4:10 PM EDT - 6 months ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:07 PM EDT - 8 months ago

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Puma Biotechnology Reports Second Quarter Financial Results

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Puma Biotechnology Reports Second Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Jul 24, 2025, 4:15 PM EDT - 9 months ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Puma Biotechnology Reports First Quarter Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Puma Biotechnology Reports First Quarter Financial Results

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Apr 30, 2025, 6:00 AM EDT - 1 year ago

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Apr 28, 2025, 3:03 PM EDT - 1 year ago

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Apr 24, 2025, 4:11 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Mar 5, 2025, 5:30 PM EST - 1 year ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 4:15 PM EST - 1 year ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:15 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 23, 2024, 9:01 AM EST - 1 year ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 20, 2024, 8:57 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jul 18, 2024, 4:10 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 3, 2024, 2:33 PM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

Jun 2, 2024, 10:01 AM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

Puma Biotechnology to Join Russell 3000 Index

May 28, 2024, 9:00 AM EDT - 2 years ago

Puma Biotechnology to Join Russell 3000 Index

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 23, 2024, 5:15 PM EDT - 2 years ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Apr 18, 2024, 4:15 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Mar 20, 2024, 8:30 AM EDT - 2 years ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 4:05 PM EST - 2 years ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 22, 2024, 4:10 PM EST - 2 years ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 4:10 PM EST - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Feb 13, 2024, 8:30 AM EST - 2 years ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 4:07 PM EST - 2 years ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Dec 11, 2023, 8:30 AM EST - 2 years ago

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Oct 19, 2023, 4:14 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Sep 21, 2023, 4:10 PM EDT - 2 years ago

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 4:07 PM EDT - 2 years ago

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Jul 20, 2023, 4:15 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Jun 4, 2023, 9:00 AM EDT - 3 years ago

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Apr 20, 2023, 4:15 PM EDT - 3 years ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Mar 14, 2023, 8:30 AM EDT - 3 years ago

Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

Mar 2, 2023, 4:05 PM EST - 3 years ago

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care Conference

Feb 28, 2023, 4:15 PM EST - 3 years ago

Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

Feb 16, 2023, 4:31 PM EST - 3 years ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results

Jonnyking
Jonnyking Apr. 8 at 10:09 PM
$PBYI It is coming?
3 · Reply
focafoca99
focafoca99 Apr. 3 at 9:04 PM
$PBYI granted inducement RSUs covering 31,625 shares to five new non-executive employees.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 2 at 3:53 PM
$PBYI Share Price: $6.93 Contract Selected: Sep 18, 2026 $10 Calls Buy Zone: $0.21 – $0.26 Target Zone: $0.40 – $0.49 Potential Upside: 79% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MahiMe
MahiMe Mar. 30 at 7:08 PM
$PBYI Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 16 at 7:54 PM
$PBYI RSI: 33.64, MACD: -0.1848 Vol: 0.59, MA20: 6.50, MA50: 6.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 14 at 2:54 PM
Big opportunity in HER2 at $RADX (Radiopharm Theranostics) $CELC $SMMT $PBYI
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 4:41 PM
$IRWD vs. $PBYI — Which small-cap biotech actually has the edge right now? Both companies are building around a single commercial drug, and sales from those therapies are expected to support their 2026 revenues—GI treatments for Ironwood and cancer therapy from Puma Biotechnology. That puts a lot of weight on how those products perform. ⚖️ See which stock looks like the better buy 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-teaser-37187&ADID=SYND_STOCKTWITS_TWEET_2_2883283_TEASER_37187
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 3:41 PM
$IRWD vs. $PBYI: Which Biotech Stock is the Better Bet? 🤔 Ironwood's Linzess sales outlook shows a promising 54% revenue boost in 2026, while Puma's Nerlynx faces a cautious growth path despite rising demand. Plus, IRWD's EPS is expected to increase by 533% in 2026! 🚀 Discover why Ironwood might be the smarter pick here 👉 https://www.zacks.com/stock/news/2883283/irwd-vs-pbyi-which-small-cap-biotech-stock-is-a-better-buy?cid=sm-stocktwits-2-2883283-body-37188&ADID=SYND_STOCKTWITS_TWEET_2_2883283_BODY_37188
0 · Reply
Jonnyking
Jonnyking Mar. 11 at 5:20 PM
$PBYI Alan, for once, please share the positive data with us, you promised on Q4 2025, then Q1 2026 and now Q2 2026.... Only the positive data can save you and us
2 · Reply
free2dream
free2dream Mar. 5 at 5:21 PM
$PBYI how is this valued at only 313M market cap ?Seems undervalued
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 3 at 4:40 PM
$PBYI Current Stock Price: $6.17 Contracts to trade: $5.0 PBYI Mar 20 2026 Call Entry: $1.05 Exit: $1.86 ROI: 77% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
StockScanners
StockScanners Mar. 3 at 6:37 AM
$PBYI keep watch if this holds above 6.05
0 · Reply
PSDL75
PSDL75 Mar. 2 at 8:08 PM
$PBYI trading around Jonny is profitable
1 · Reply
tsingyuanTemp
tsingyuanTemp Mar. 2 at 8:07 PM
$PBYI you guys listen to the confernece? Nothing big for the two phase 2 trials. Did I miss anything?
1 · Reply
MahiMe
MahiMe Mar. 2 at 3:05 PM
$PBYI conference today..
0 · Reply
PSDL75
PSDL75 Mar. 2 at 12:09 PM
$PBYI Jonny bearish with a low price target...Cinderella bearish... can't be a bigger buy sign....red to green here on a bad day or week.. Today will be interesting
0 · Reply
Jonnyking
Jonnyking Feb. 28 at 1:19 AM
$PBYI dang, no data release? the only way that we can be saved is the release of promising data and Alan hit selling button, otherwise, we are heading to 4-5.... lost all the gains from last 3 months in one day, no fun
2 · Reply
Jruiner
Jruiner Feb. 27 at 10:17 PM
$PBYI par for the course if you’ve been here long enough
1 · Reply
ZacksResearch
ZacksResearch Feb. 27 at 6:53 PM
$PBYI beats big… and still gets crushed 14% after hours. What gives? ⚠️ Q4 earnings topped estimates and revenue jumped 28%, a strong print by any standard. But the weak 2026 outlook spooked the market, overshadowing the beat and triggering a sharp selloff. Is this an overreaction or a warning shot? Full breakdown here 👉 https://www.zacks.com/stock/news/2876997/pbyi-q4-earnings-sales-beat-estimates-stock-down-on-weak-2026-view?cid=sm-stocktwits-2-2876997-teaser-35605&ADID=SYND_STOCKTWITS_TWEET_2_2876997_TEASER_35605
0 · Reply
Bazzil
Bazzil Feb. 27 at 6:32 PM
$PBYI is this drop also related to Zongertinib approval? Next gen her 2 TK inhibitor with better side effect profile.
1 · Reply
ZacksResearch
ZacksResearch Feb. 27 at 5:53 PM
$PBYI Q4 earnings beat, but shares tumble 14% on weak 2026 guidance. 📉 🔹 EPS of 29 cents tops estimates 🔹 Q4 revenue up 28% YoY thanks to Nerlynx and royalty growth 🔹 Disappointing 2026 outlook: Total revenue guidance below Zacks Consensus Estimate Full analysis here 👉 https://www.zacks.com/stock/news/2876997/pbyi-q4-earnings-sales-beat-estimates-stock-down-on-weak-2026-view?cid=sm-stocktwits-2-2876997-body-35604&ADID=SYND_STOCKTWITS_TWEET_2_2876997_BODY_35604
0 · Reply
PSDL75
PSDL75 Feb. 27 at 4:05 PM
$PBYI you sell Jonny and buy Cinderella...
0 · Reply